Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;3(1):66-71.
doi: 10.3892/etm.2011.359. Epub 2011 Oct 3.

Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer

Tomofumi Osako  1 , Reiki Nishimura, Yasuhiro Okumura, Yasuo Toyozumi, Nobuyuki Arima
Affiliations

Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer

Tomofumi Osako et al. Exp Ther Med. 2012 Jan.

Abstract

Estrogen receptor (ER) and progesterone receptor (PgR) status are predictive factors for the clinical and pathological response to neoadjuvant chemotherapy for operable breast cancer. However, it remains unclear as to how the proportion of ER-positive or PgR-positive tumor cells affects the response to neoadjuvant chemotherapy. We examined the correlation of the proportion of ER-positive or PgR-positive tumor cells with the clinical and pathological response to neoadjuvant chemotherapy for operable human epidermal growth factor receptor 2 (HER2)-negative breast cancer. From April 2002 to October 2010, 103 patients received neoadjuvant chemotherapy containing epirubicin and taxane in our clinic. A clinical response was observed in 86 (83%) patients, and a pathological complete response (pCR) was observed in 16 (16%) patients. Fourteen (30%) of 46 patients with ER-negative tumors achieved pCR and 15 (26%) of 57 patients with PgR-negative tumors achieved pCR. Patients with more than 30% ER-positive tumor cells or more than 1% PgR-positive tumor cells did not achieve pCR. No significant correlation was observed between pCR and the menopausal status, tumor size, grade and Ki-67 expression. In univariate analysis, pCR was associated with the ER status (p=0.001), PgR status (p=0.0001) and chemotherapy regimens (p=0.03). Multivariate analysis revealed that ER and PgR status were significant factors for pCR, and patients with ER-negative tumors were 18.6 times more likely to achieve pCR than those with greater than or equal to 30% ER-positive tumor cells (p=0.006; 95% confidence interval 2.3-149.9). We demonstrated a predictive significance of the proportion of ER-positive or PgR-positive tumor cells in the response to neoadjuvant chemotherapy for operable HER2-negative breast cancer. ER-negativity (<1%) was a significant predictive factor for achieving pCR in multivariate analysis. Conversely, patients with more than 30% ER-positive tumor cells or more than 1% PgR-positive tumor cells may not achieve pCR.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Frequency distribution according to the proportion of ER-positive-staining tumor cells among 103 primary breast cancers. The bar graph shows the bimodal distribution; most of the ER-negative tumors were ER-absent and most of the ER-positive tumors were >90% ER-positive. The gray bars indicate the number of patients who achieved pCR. Most of the patients who achieved pCR had ER-absent tumors, and patients whose tumor had >30% ER-positive cells did not achieve pCR.
Figure 2.
Figure 2.
Frequency distribution according to the proportion of PgR-positive-staining tumor cells among 103 primary breast cancers. The gray bars indicate the number of patients who achieved pCR. Most of the PgR-negative tumors were PgR-absent. Most of the patients who achieved pCR had PgR-absent tumors, and patients whose tumor had >1% PgR-positive cells did not achieve pCR.
Figure 3.
Figure 3.
Disease-free survival according to pCR in all patients.
Figure 4.
Figure 4.
Overall survival according to pCR in all patients.
Figure 5.
Figure 5.
Disease-free survival according to pCR in patients with ER-negative and ER-positive tumors.
Figure 6.
Figure 6.
Overall survival according to pCR in patients with ER-negative and ER-positive tumors.
See this image and copyright information in PMC

References

    1. Van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224–4237. - PubMed
    1. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from the National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–4174. - PubMed
    1. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–2685. - PubMed
    1. Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 1998;9:1179–1184. - PubMed
    1. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS) Ann Oncol. 1999;10:47–52. - PubMed